Dr Ogdie answers our questions about achieving minimal disease activity among patients with psoriatic arthritis treated with biologic and targeted synthetic DMARDs.
Dr Ogdie answers our questions about achieving minimal disease activity among patients with psoriatic arthritis treated with biologic and targeted synthetic DMARDs.
Patients with psoriatic arthritis who had not responded to or tolerated other therapies achieved significant improvements over 52 weeks when treated with risankizumab 150 mg.
Patients with psoriatic arthritis who had not responded to or tolerated other therapies achieved significant improvements over 52 weeks when treated with risankizumab 150 mg.
During her presentation on diagnosis, manifestations, and outcomes of rheumatoid arthritis (RA), Dr Victoria Konzett defined RA flares based on SDAI and CDAI.
During her presentation on diagnosis, manifestations, and outcomes of rheumatoid arthritis (RA), Dr Victoria Konzett defined RA flares based on SDAI and CDAI.
